

A1
ant

41. (NEW) The vaccine of claim 32 further comprising gentamicin.

42. (NEW) The vaccine of claim 32 comprising EHV-1 KyA virus inactivated by treatment with a chemical inactivating agent which includes binary ethylenimine.

43. (NEW) The vaccine of claim 32 wherein the cross-linked acrylic acid polymer has a viscosity of no more than about 20,000 cPs at 20 rpm as a 1.0 wt.% aqueous solution at pH 7.5.

REMARKS

Prior to entry of this Amendment, Claims 1-31 were pending in the application. In this Amendment, Claims 23-26 and 28-31 have been cancelled without prejudice and new Claims 32-43 have been added. Accordingly, after entry of this Amendment, Claims 1-22, 27, 28, and 32-43 are pending in the application. Applicant has directed new independent Claim 32 to elected Group 1, which is drawn to an inactivated EHV vaccine. Claims 33-43 all depend from Claim 32.

Support for the new claims may be found in the specification and claims, as originally filed. In particular, support for new Claim 32 may be found in the specification on page 3 and in originally filed Claims 13 and 14. Support for new Claims 33-40 may be found in originally filed Claims 4-11, respectively. Support for new Claim 41 may be found in the specification as filed on pages 10-11 and 16. Support for new Claim 42 may be found in originally filed Claim 15. Support for new Claim 43 may be found in originally filed Claim 16. As such, Applicants respectfully request entry of the amendments to the claims.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date 10/22/2002

By M. Scott McBride

FOLEY & LARDNER
Customer Number: 26371



26371

PATENT TRADEMARK OFFICE

Telephone: (414) 297-5529
Facsimile: (414) 297-4900

M. Scott McBride
Attorney for Applicant
Registration No. 52,008